Camereyes

Company Overview

Snapshot

Founded in February 2015 by Udi Gordon, Barak Azmon, and David Rosenblatt, Camereyes operates with 1–10 employees. The company has raised $950,000 across two funding rounds from VLX Ventures. In April 2018, Camereyes secured a Seed funding round.

Business overview

Camereyes developed an end-to-end solution for detecting and monitoring diabetic retinopathy, leveraging optics and deep-learning algorithms. Its InSight product provides a low-cost, fully automated solution for capturing fundus images, particularly suitable for remote locations without requiring pupil dilation. The company serves the digital healthcare and medical devices sectors, utilizing a network of professional reading centers supported by machine-learning algorithms to analyze images and generate reports for clinics, insurance companies, and doctors globally.

Strategic signal

In December 2015, Camereyes announced it had raised $650,000, signaling early investor confidence in its deep-learning imaging platform for diabetic retinopathy. This initial funding validated the company's innovative approach to non-invasive diagnostics and its potential to address critical healthcare needs in underserved areas, positioning it for further development in the health tech and life sciences sector.

Company Intelligence Q&A

What is Camereyes' primary focus?

Camereyes focuses on developing a deep-learning imaging platform designed to prevent diabetic retinopathy through early detection and monitoring.

When was Camereyes founded?

Camereyes was founded in February 2015.

Who are the founders of Camereyes?

Camereyes was founded by Udi Gordon, Barak Azmon, and David Rosenblatt.

What is the core technology behind Camereyes' solution?

Camereyes' InSight solution utilizes optics and deep-learning algorithms to provide a low-cost, fully automated system for detecting and monitoring diabetic retinopathy.

What was a key funding event for Camereyes?

In April 2018, Camereyes secured a Seed funding round from VLX Ventures.